Evidence map›Paper›PMID 38827745›Full record

ArticleFrontiers in immunology2024

Activation of TLR9 signaling suppresses the immunomodulating functions of CD55

Ting Jiang, Yiming Li, Xingping Huang, Preethi Jayakumar, Timothy R Billiar, Meihong Deng

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ting Jiang *Department of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Yiming Li *Department of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Xingping HuangInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, New York, NY, United States.
Preethi JayakumarInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, New York, NY, United States.
Timothy R BilliarDepartment of Surgery, University of Pittsburgh, Pittsburgh, PA, United States.
Meihong DengInstitute of Molecular Medicine, Feinstein Institutes for Medical Research, New York, NY, United States.

Funding

Role of Toll-like Receptor 9 in Fibroblastic Reticular Cell-based Therapy for Intra-abdominal SepsisR01AI152044 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DENG, MEIHONG · 2020 to 2024
$2.1M
NIAID NIH HHS R01 AI152044
6 · The paper itself

Abstract

Fibroblastic reticular cells (FRCs) are a subpopulation of stromal cells modulating the immune environments in health and disease. We have previously shown that activation of TLR9 signaling in FRC in fat-associated lymphoid clusters (FALC) regulate peritoneal immunity via suppressing immune cell recruitment and peritoneal resident macrophage (PRM) retention. However, FRCs are heterogeneous across tissues and organs. The functions of each FRC subset and the regulation of TLR9 in distinct FRC subsets are unknown. Here, we confirmed that specific deletion of TLR9 in FRC improved bacterial clearance and survival during peritoneal infection. Furthermore, using single-cell RNA sequencing, we found two subsets of FRCs (CD55

Indexed as

FibroblastsPeritonitisSignal TransductionToll-Like Receptor 9AnimalsDisease Models, AnimalHumansImmunomodulationMaleMiceMice, Inbred C57BLMice, KnockoutTlr9 protein, mouseToll-Like Receptor 9fat-associated lymphoid clusterfibroblastic reticular cellsperitoneal immunityperitonitisTLR9

Identifiers

PMID38827745
PMCPMC11140099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.